BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Stereotaxis, Inc. (STXS) Executives Take Pay Cuts


10/13/2011 2:03:54 PM

Kelsey Volkmann, Web Editor - St. Louis Business Journal

The senior management at Stereotaxis, including CEO Michael Kaminski, have taken voluntary pay cuts through 2013.

Kaminski took a 16 percent cut and now makes a base salary of $352,000, according to a regulatory filing today with the Securities and Exchange Commission.

Chief Technology and Operators Officer Douglas Bruce took a 10 percent pay cut and now makes $292,500.

Senior Vice President for Marketing and Business Development Frank Cheng took a 10 percent pay cut and now makes $256,500.

Senior Vice President and General Counsel and Secretary Karen Witte Duros took a 10 percent cut and now makes $243,000.

Vice President for Human Resources David Giffin took a 10 percent pay reduction and now makes $180,000.

In order to keep the executives from leaving the company, the board granted shares of restricted stock to each of them this week that will be subject to vesting at the end of an 18-month period ending on March 31, 2013, according to the filing.

St. Louis-based Stereotaxis, which makes cardiology instruments to treat coronary artery disease and arrhythmias, has signed a loan modification agreement with Silicon Valley Bank that requires the company raise $10 million in 60 days.

Last week, St. Louis law firm Carey, Danis & Lowe and San Diego law firm Robbins Umeda LLP filed a class-action lawsuit against Stereotaxis in federal court in St. Louis alleging that executives made false statements that caused shares of the company’s stock to trade at artificially high prices. Stereotaxis (NASDAQ: STXS) closed Wednesday at $1.11 a share, down from $3.95 a share Feb. 28.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES